

ASX Announcement

18 September 2026

Appointment of Professor Ian Meredith AM to the Cochlear Board

Cochlear Limited (ASX: COH) today announced the appointment of Professor Ian Meredith, AM to the Cochlear Board. Prof. Meredith's appointment as an independent Non-executive Director will become effective on 1 December 2026.

Prof. Meredith has more than 30 years' experience merging patient care, clinical research and the development and commercialisation of transformative healthcare solutions. Most recently, he served as Executive Vice President and Global Chief Medical Officer at Boston Scientific Corporation until 2023, where he led clinical innovation and medical affairs across the global organisation, overseeing 15,000 healthcare products, medical devices and technologies.

Prof. Meredith has significant experience in evaluating technologies for new therapies, product portfolio management, governance and M&A across multiple healthcare domains and disciplines. He is also a globally recognised interventional cardiologist and professor of medicine.

Prof. Meredith currently serves on the Boards of Transverse Medical, Inc and Alleviant Medical, Inc., US medical technology companies developing innovative cardiovascular devices and therapies, as well as on government-owned and not-for-profit organisations supporting healthcare delivery, medical research commercialisation and life sciences innovation.

Cochlear Chair, Alison Deans, said, "I am delighted that Ian has agreed to join our Board. He brings a unique combination of clinical, scientific and commercial expertise, underpinned by deep experience in medical technology innovation and patient care.

"His experience leading clinical innovation, evidence generation and medical affairs for a global healthcare technology company, together with his understanding of the pathways through which new therapies become established standards of care, will provide invaluable insights to our Board."

Prof. Meredith will become a member of the Medical Science Committee, the Product & Services Innovation Committee and the Nomination Committee and resides in Melbourne, Australia.

For further information, please contact:

Analysts

Kristina Devon
VP Corporate Strategy and
Investor Relations
kdevon@cochlear.com
Ph: + 61 2 9073 4194

Analysts

Cale Brown
Director Investor Relations
cabrown@cochlear.com
Ph: + 61 2 9072 2769

Media

Jennifer Stewart
VP Communications, Brand &
Digital Marketing
jstewart@cochlear.com
Ph: +61 2 9073 4186

This announcement is authorised by the Cochlear Board of Directors.